[go: up one dir, main page]

SG11201600379TA - Polyconjugates for delivery of rnai triggers to tumor cells in vivo - Google Patents

Polyconjugates for delivery of rnai triggers to tumor cells in vivo

Info

Publication number
SG11201600379TA
SG11201600379TA SG11201600379TA SG11201600379TA SG11201600379TA SG 11201600379T A SG11201600379T A SG 11201600379TA SG 11201600379T A SG11201600379T A SG 11201600379TA SG 11201600379T A SG11201600379T A SG 11201600379TA SG 11201600379T A SG11201600379T A SG 11201600379TA
Authority
SG
Singapore
Prior art keywords
polyconjugates
vivo
delivery
tumor cells
rnai triggers
Prior art date
Application number
SG11201600379TA
Inventor
Weijun Cheng
So Wong
Aaron M Almeida
David B Rozema
Andrei V Blokhin
Jeffrey C Carlson
Original Assignee
Arrowhead Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Res Corp filed Critical Arrowhead Res Corp
Publication of SG11201600379TA publication Critical patent/SG11201600379TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052Val-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • C07K5/0817Tripeptides with the first amino acid being basic the first amino acid being Arg
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3513Protein; Peptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/353Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535Nitrogen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
SG11201600379TA 2013-08-07 2014-08-06 Polyconjugates for delivery of rnai triggers to tumor cells in vivo SG11201600379TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361863056P 2013-08-07 2013-08-07
US14/452,626 US9487556B2 (en) 2013-08-07 2014-08-06 Polyconjugates for delivery of RNAi triggers to tumor cells in vivo
PCT/US2014/049851 WO2015021092A1 (en) 2013-08-07 2014-08-06 Polyconjugates for delivery of rnai triggers to tumor cells in vivo

Publications (1)

Publication Number Publication Date
SG11201600379TA true SG11201600379TA (en) 2016-02-26

Family

ID=52449177

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201600379TA SG11201600379TA (en) 2013-08-07 2014-08-06 Polyconjugates for delivery of rnai triggers to tumor cells in vivo

Country Status (13)

Country Link
US (3) US9487556B2 (en)
EP (1) EP3030244B1 (en)
JP (1) JP6433001B2 (en)
KR (1) KR20160035081A (en)
CN (1) CN105451743B (en)
AU (1) AU2014306021B2 (en)
CA (1) CA2919088A1 (en)
EA (1) EA201690051A1 (en)
IL (1) IL243941B (en)
MX (1) MX2016001006A (en)
SG (1) SG11201600379TA (en)
TW (1) TWI685347B (en)
WO (1) WO2015021092A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600379TA (en) * 2013-08-07 2016-02-26 Arrowhead Res Corp Polyconjugates for delivery of rnai triggers to tumor cells in vivo
EP3270903B1 (en) * 2015-03-17 2020-05-06 Arrowhead Pharmaceuticals, Inc. Disulfide-containing alkyne linking agents
CN113493789A (en) 2015-03-17 2021-10-12 箭头药业股份有限公司 Compositions and methods for inhibiting gene expression of factor XII
MX382851B (en) 2015-05-29 2025-03-13 Arrowhead Pharmaceuticals Inc BIOLOGICALLY CLEAVABLE TETRAPEPTIDE BINDING AGENTS.
EA201792103A1 (en) * 2015-05-29 2018-06-29 Эрроухэд Фармасьютикалз, Инк. COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES
CN108779184B (en) * 2015-12-29 2023-04-21 高德美控股有限公司 Method for deacetylation of biopolymers
EP3252082A1 (en) * 2016-05-31 2017-12-06 Galderma S.A. Method for deacetylation of biopolymers
PT3623390T (en) * 2016-05-31 2023-10-27 Galderma Sa Carbohydrate crosslinker
EP3630189A4 (en) 2017-05-24 2021-06-23 The Board of Regents of The University of Texas System LINKER FOR ANTIBODY MEDICINAL CONJUGATES
BR112020021949A2 (en) 2018-04-27 2021-01-26 Arrowhead Pharmaceuticals, Inc. ligands targeting integrin and their uses
AU2020207050A1 (en) 2019-01-09 2021-06-17 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
CN110240551B (en) * 2019-06-25 2022-02-11 成都郑源生化科技有限公司 Preparation method of Fmoc-beta-Ala-Gly-OH
IL293540A (en) 2019-12-02 2022-08-01 Galderma Holding SA High molecular weight aesthetic preparations
CN113004515B (en) * 2021-03-02 2023-02-24 厦门大学附属中山医院 Hyaluronic acid-like polyamino acid derivative, and preparation method and application thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO118289B1 (en) * 1995-08-30 2003-04-30 Gd Searle & Co Chicago Phenyl carbonyl urea derivatives and pharmaceutical composition
EP0889877B1 (en) 1996-03-29 2001-08-29 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
EP0927045B1 (en) * 1996-09-10 2005-12-14 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
AU6067098A (en) 1997-04-07 1998-10-08 Cfpi Nufarm Preparation process for 3,4-disubstituted dinitroanilines
EP1446418B1 (en) * 2001-10-22 2012-05-23 The Scripps Research Institute Integrin targeting compounds
JP2004261024A (en) * 2003-02-28 2004-09-24 Japan Science & Technology Agency Gene therapy using peptide-modified polysaccharide
WO2004090108A2 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals Irna conjugates
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
CA2581869A1 (en) * 2004-11-04 2006-05-18 Raul Andino Syntheses of polyamine conjugates of small interfering rnas (si-rnas) and conjugates formed thereby
JP2008537752A (en) * 2005-04-12 2008-09-25 イントラディグム コーポレイション RNAi therapeutic compositions and methods for treating cancer and other neovascular diseases
KR101133799B1 (en) 2006-08-18 2012-04-24 에프. 호프만-라 로슈 아게 Polyconjugates for in vivo delivery of polynucleotides
US8017109B2 (en) 2006-08-18 2011-09-13 Roche Madison Inc. Endosomolytic poly(acrylate) polymers
JP2010503414A (en) * 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド Polymer composites containing positively charged moieties
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
EP2379083B1 (en) 2008-12-18 2017-08-16 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
HRP20160093T1 (en) 2010-02-24 2016-02-26 Arrowhead Research Corporation TARGET DELIVERY PREPARATIONS
US8501930B2 (en) * 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
KR20130108655A (en) * 2010-12-29 2013-10-04 에프. 호프만-라 로슈 아게 Small molecule conjugates for intracellular delivery of nucleic acids
MX347298B (en) * 2010-12-29 2017-04-21 Arrowhead Res Corp In vivo polynucleotide delivery conjugates having enzyme sensitive linkages.
KR20140051357A (en) 2011-08-26 2014-04-30 애로우헤드 리서치 코오포레이션 Poly(vinyl ester) polymers for in vivo nucleic acid delivery
CN104144706B (en) * 2012-01-27 2017-03-29 弗·哈夫曼-拉罗切有限公司 Integrin antagonist conjugates for targeted delivery to cells expressing α-V-β-3
EP2806896B1 (en) 2012-01-27 2018-01-03 F. Hoffmann-La Roche AG Chitosan covalently linked with small molecule integrin antagonist for targeted delivery
CN103764153A (en) 2012-04-18 2014-04-30 箭头研究公司 Poly(acrylate) polymers for in vivo nucleic acid delivery
SG11201600379TA (en) * 2013-08-07 2016-02-26 Arrowhead Res Corp Polyconjugates for delivery of rnai triggers to tumor cells in vivo

Also Published As

Publication number Publication date
EP3030244B1 (en) 2021-04-21
AU2014306021A1 (en) 2016-01-28
TWI685347B (en) 2020-02-21
WO2015021092A1 (en) 2015-02-12
CN105451743B (en) 2019-11-19
US9487556B2 (en) 2016-11-08
AU2014306021A2 (en) 2016-11-24
JP2016535058A (en) 2016-11-10
MX2016001006A (en) 2016-04-19
AU2014306021B2 (en) 2018-12-13
CN105451743A (en) 2016-03-30
EA201690051A1 (en) 2016-06-30
IL243941B (en) 2019-06-30
CA2919088A1 (en) 2015-02-12
US20170022497A1 (en) 2017-01-26
HK1220397A1 (en) 2017-05-05
JP6433001B2 (en) 2018-12-05
EP3030244A4 (en) 2017-06-28
TW201601742A (en) 2016-01-16
US20150045573A1 (en) 2015-02-12
IL243941A0 (en) 2016-04-21
KR20160035081A (en) 2016-03-30
US20190062748A1 (en) 2019-02-28
EP3030244A1 (en) 2016-06-15

Similar Documents

Publication Publication Date Title
IL243941A0 (en) Polyconjugates for delivery of rnai triggers to tumor cells in vivo
IL244113B (en) Selective delivery of material to cells
ZA201507790B (en) Enhanced adoptive cell therapy
PT2768493T (en) PHYTOCANABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER
PL3234107T3 (en) B cells for in vivo delivery of therapeutic agents
EP2971040A4 (en) Methods of cell culture
EP2971014A4 (en) Methods of cell culture
EP2872036A4 (en) In vivo biosensor
ZA201406726B (en) Methods and composition related to brown adipose-like cells
PL2925223T3 (en) Improved methods of assessing metabolic function
IL290429A (en) Improved methods of genetically modifying animal cells
SG10201800017RA (en) Cell preparation including fat cell
GB2510826B (en) Improvements in or relating to release of a beneficial substance from a bolus
ZA201408383B (en) Improved endoglucanases for treatment of cellulosic material
SG11201502214PA (en) Adipose tissue cells
GB201516123D0 (en) In vivo cell imaging
PL3082858T3 (en) Adrenomedullin binder for use in therapy of cancer
PL2950663T3 (en) Methods to increase silage quality in crops
GB201302197D0 (en) Method of increasing lipid accumulation in pulcherrima cells
GB201304514D0 (en) Cell delivery
EP2738248A4 (en) Method for manufacture in vitro vascularized tissue
EP2738249A4 (en) Method for manufacturing in vitro vascularized tissue
EP2720720A4 (en) Combination therapy to prevent dcis formation and progression to breast cancer
IL233166A0 (en) Programmable cell model for determining cancer treatments
GB201216933D0 (en) Adipose tissue cells